Given the paucity of data in type 1 diabetes concerning lipoprotein-associated phospholipase A 2 (Lp-PLA 2 ), we examined its prospective relationship with coronary artery disease (CAD), as well as the effect of modification by C-reactive protein (CRP) and haptoglobin genotype, in individuals with type 1 diabetes who are at an increased risk for CAD due to also having macroalbuminuria (n596). Although Lp-PLA 2 activity was univariately predictive of CAD (HR51.54 per SD, p50.009), this relationship was not significant after covariate adjustment (p50.59). There was a significant interaction between Lp-PLA 2 and CRP (p50.02), i.e. those with both markers greater than the median level were more likely to have a CAD event than those persons with low levels of both (HR52.89, p50.06). When stratified by haptoglobin genotype, Lp-PLA 2 was predictive of CAD in persons with the 2/1 (HR52.40, p50.05), but not 2/2 (HR50.66, p50.27), genotype. The association between Lp-PLA 2 activity and CAD differs by CRP and haptoglobin genotype in this group of persons with type 1 diabetes and macroalbuminuria.
Introduction
As atherosclerosis has been increasingly considered an inflammatory process, 1 researchers have turned their focus to evaluating the prognostic value of biomarkers of inflammation. Lipoprotein-associated phospholipase A 2 (Lp-PLA 2 ) has recently been added to this biomarker list. Lp-PLA 2 is an enzyme produced by macrophages in advanced, rupture prone, atherosclerotic plaques. It circulates bound primarily to lipoproteins in the plasma and hydrolyses oxidized lowdensity lipoprotein (LDL) generating two pro-inflammatory mediators, oxidized free fatty acids and lysophosphatidylcholine. Through this action on LDL particles, it was therefore thought that Lp-PLA 2 may be directly involved in the formation of atherosclerotic lesions. 2 However, it is now recognized that Lp-PLA 2 induces a broad range of biological responses, is involved in a wide variety of biological actions 3 and can thus be attributed a variety of properties, including both pro-inflammatory 4, 5 and anti-inflammatory. [6] [7] [8] Nevertheless, increasing evidence from epidemiological studies in humans suggests that Lp-PLA 2 is independently associated with coronary artery disease (CAD) risk. [9] [10] [11] [12] [13] [14] [15] [16] [17] Thus far, the presence of such an association has not been evaluated among individuals with type 1 diabetes (T1D), despite persons with high levels of either marker alone. 12 While CRP has been found to be associated with vascular disease in non-diabetic 27, 28, [30] [31] [32] [33] [34] and type 2 diabetic 29, 35, 36 subjects, the relationship between CRP and CAD in T1D is not clear. [37] [38] [39] Recently, several longitudinal studies have provided evidence that a polymorphism of the haptoglobin gene more than doubles cardiovascular disease risk among persons with type 2 diabetes. [40] [41] [42] We have also shown that the haptoglobin genotype is associated with CAD in the Pittsburgh Epidemiology of Diabetes Complications (EDC) study of T1D, with the 2/2 genotype conferring the greatest risk. 43 We assessed the prospective association between Lp-PLA 2 with CAD risk, and examined whether this relationship is modified by CRP and haptoglobin genotype, in a group of individuals with T1D, who are at particularly high risk for CAD due to also having diabetic renal disease. 24, [44] [45] [46] [47] [48] [49] We also examined whether high-density lipoprotein (HDL) or LDL cholesterol concentration modified the prediction of CAD by Lp-PLA 2 .
Methods

Study population
The participants were identified from the EDC study, a prospective study of childhood-onset (<18 years old at diagnosis) T1D. All participants were diagnosed with T1D or seen within 1 year of diagnosis at the Children's Hospital of Pittsburgh between 1950 and 1980. A total of 658 individuals met the eligibility criteria and participated in the EDC baseline examination, conducted between 1986 and 1988, and participants were assessed biennially thereafter. Lp-PLA 2 activity was measured on a subgroup of the EDC study cohort with macroalbuminuria (albumin excretion rate ≥200 μg/min) at study baseline; the current analyses were performed on these 96 individuals.
Measurement of biomarkers
Lp-PLA 2 activity was assayed using a colorimetric assay (diaDexus, South San Francisco, CA, USA). CRP was measured using a high-sensitivity turbidimetric method (reagents developed by Carolina Liquid Chemicals, Brea, CA, USA). A PureGene kit (Gentra Systems, Minneapolis, MN) was used to isolate high-molecular-weight genomic DNA and haptoglobin was genotyped by the amplification method of Koch et al. 50 Genotypes were assigned visually by comparison with controls of known genotype. 
Ascertainment of CAD outcome
Clinical measurements
Participants completed questionnaires concerning demographic and medical history information. Weight was measured using a balanced-beam scale with clothing during the clinical examination. Height was measured using the clinic stadiometer, with the Frankfort plane held horizontal. Body mass index (BMI) was calculated as weight in kilograms divided by height in metres squared. Waist circumference was measured twice at the midpoint between the highest point of the iliac crest and the lowest part of the costal margin in the midaxillary line. If the two measurements differed by more than 0.5 cm, a third measurement was performed. The mean of the waist measurements was recorded as waist circumference. Hip girth measurement was performed at the widest point of the glutei, usually at the level of the greater femoral trochanter, and the mean of two measures was recorded as the hip circumference, in the same manner as the waist measurements. The ratio of the waist circumference to the hip circumference (WHR) was used in analyses. For the first 18 months of the study, fasting blood samples were analysed for HbA1 (microcolumn cation exchange; Isolab, Akron, OH, USA). For the remainder of the baseline examinations, automated high-performance liquid chromatography (HPLC; Diamat, BioRad, Hercules, CA, USA) was performed. The two assays were highly correlated (r50.95; Diamat HbA1 5 -0.18 1 1.00 [Isolab HbA1]). For analysis purposes, the HbA1 values were converted to a Diabetes Control and Complications Trial (DCCT)-aligned value using a regression equation derived from duplicate assays (DCCT HbA1c 5 0.14 1 0.83 [EDC HbA1]). Serum total cholesterol and triglycerides were determined enzymatically, 51,52 HDL cholesterol was determined using a precipitation technique with a modification 53 of the Lipid Research Clinics method 54 and LDLcholesterol levels were calculated from the measurements of total cholesterol, triglycerides and HDL cholesterol using the Friedewald equation. 55 All blood samples were taken after at least 8 hours of fasting. Three seated blood pressure readings were taken with a random-zero sphygmomanometer and the mean of the second and third readings was used in analyses, according to the Hypertension Detection and Follow-up Program Protocol. 56 Hypertension was defined as at least 140/90 mmHg or use of antihypertensive medication. White blood cell count (WBC) was obtained using a counter S-plus IV.
Statistical Analyses
Baseline characteristics were compared between CAD cases and non-cases using Student's t-test, Wilcoxon's two-sample test for non-normally distributed variables, and a chi-squared test for binary variables. T1D durationadjusted correlations between Lp-PLA 2 and CAD risk factors were assessed using Pearson partial correlations or Spearman partial correlations, when variables were not normally distributed. Cox proportional hazard models were used to estimate the relative risk of CAD associated with a one-SD increase in Lp-PLA 2 activity. Follow-up time was defined as the time from the baseline examination to the date of the first CAD event or, for non-cases, follow-up continued until death, last contact or censoring during 18-year follow-up. Adjusted regression models were built using forward selection. As age and duration of diabetes are highly correlated in this cohort (r50.85), only duration was made available to multivariate models. The proportional hazards assumption was assessed visually by plotting the log cumulative hazard function of CAD by Lp-PLA 2 activity and verified by showing that time-dependent Lp-PLA 2 interaction variables were not statistically significant. An Lp-PLA 2 -CRP interaction term was tested with respect to risk of developing CAD and additional proportional hazards models were fit to examine combined categories of the two biomarkers, using indicator variables, in order to further explore the nature of the interaction. The combined categories were created by stratifying baseline Lp-PLA 2 and CRP by their median values and combining as follows:
Low Lp-PLA 2 -Low CRP, Low Lp-PLA 2 -High CRP, High Lp-PLA 2 -Low CRP, High Lp-PLA 2 -High CRP. Analyses were repeated after stratifying by haptoglobin genotype in the participants with available genetic material (n580). Persons with the 2/1 genotype were compared with those with the higher risk genotype (2/2). Owing to the low frequency of the 1/1 genotype, those persons (n510) were excluded from the genotype comparison analysis. All analyses were performed using SAS 9.1.3 (SAS Institute Inc., Cary, NC). Table 1 . Lp-PLA 2 activity was significantly higher in persons who went on to develop CAD compared with those who did not (p50.02, Table 1 ). After adjusting for LDL cholesterol, the difference in Lp-PLA 2 by CAD status was no longer statistically significant (p50.12). Adjustment for HDL also attenuated the difference in Lp-PLA 2 by CAD cases and non-cases, but it remained statistically significant (p50.04). Lp-PLA 2 activity was significantly and positively correlated with total and LDL cholesterol, diastolic blood pressure, WBC and WHR, but not BMI (Table 2 ). Lp-PLA 2 also had an inverse significant correlation with HDL cholesterol and marginally significant positive correlations with triglycerides and systolic blood pressure ( Table 2 ).
Results
A comparison of baseline characteristics between CAD cases and non-cases is shown in
In an unadjusted Cox proportional hazards model, higher Lp-PLA 2 activity was significantly associated with an increased risk of developing CAD (hazard ratio (HR) 51.54 per one-SD increase in Lp-PLA 2 activity, p50.009; Table 3 ). However, after forward selection, in a model adjusting for T1D duration, sex, CRP, LDL cholesterol, systolic blood pressure, blood pressure medication use and WBC, Lp-PLA 2 activity was no longer significantly associated with CAD risk (HR51.15, p50.59). Alternative models were fit including HDL cholesterol both in place of, and in addition to, LDL cholesterol, age in place of T1D duration, and waist circumference in place of WHR, but the results showed little difference from those presented in Table 3 (data not shown). No interactions were found between Lp-PLA 2 activity and either of the lipoproteins. An Lp-PLA 2 -CRP interaction term, added to the final model shown in Table 3 , was found to be statistically significant (p50.02).
In an unadjusted model assessing the relationship between combined categories of Lp-PLA 2 activity and CRP with CAD, those in the High Lp-PLA 2 activity-High CRP group had significantly elevated risk of developing CAD (HR53.79, p50.004) compared with the Low-Low group (Table 4) . After covariate adjustment, this relationship remained, but was a little attenuated, with the High Lp-PLA 2 activity-High CRP group being nearly three times more likely to develop CAD than the low Lp-PLA 2 -Low CRP group (HR52.89, p50.06).
Lp-PLA 2 activity level did not differ by haptoglobin genotype, with a mean of 146.4 (SD 32.1) in the haptoglobin 2/1 genotype and 145.1 (SD 32.6) in the haptoglobin 2/2 genotype (p50.89). Although an Lp-PLA 2 activity-haptoglobin interaction term was not significant with respect to CAD incidence (p50.45), after stratifying by haptoglobin genotype, in the 2/1 genotype, the association between Lp-PLA 2 activity and CAD was statistically significant (HR51.80, p50.02) and remained so after adjustment for CRP, T1D duration, LDL-cholesterol, HbA1c and triglycerides (HR52.40, p50.05; Table 5 ). The increased HR was largely due to the addition of triglycerides into the model. In contrast, there was no apparent association between Lp-PLA 2 activity and CAD in the 2/2 genotype (unadjusted HR51.18 p50.47, fully adjusted HR50.66, p50.27; Table 5 ). The results remained similar when both genotype models were forced to contain the same covariates for adjustment, namely, T1D duration, sex, LDL-cholesterol, ln(triglycerides) and CRP, covariates that were significant predictors of CAD in an overall model of the participants with genetic data available (Hp 2/1 HR51.97 (0.98, 3.95), p50.05, Hp 2/2 HR50.56 (0.23, 1.34), p50.19). The relationship between CRP and CAD was slightly weaker in the 2/2 genotype (adjusted HR51.14, p50.01) compared with the 2/1 genotypes (adjusted HR51.63, p50.001). A comparison of the incidence of CAD per 100 person-years by stratified groups suggested that having both high Lp-PLA 2 activity and high CRP may lead to an increased risk of CAD in persons with the 2/1 genotype (11.9 events per 100 person-years compared with Model 2: Lp-PLA 2 Activity and C-reactive protein (CRP) c Model 3: Lp-PLA 2 Activity, CRP, type 1 diabetes (T1D) duration, sex d Model 4: Final model after forward selection: Lp-PLA 2 activity, CRP, T1D duration, sex, low-density lipoprotein cholesterol, systolic blood pressure, blood pressure medication use, white blood cells In addition to the variables included in the final model, the following were also made available to forward selection models: HbA1c, waist-hip ratio, triglycerides, diastolic blood pressure and smoking status the Low Lp-PLA 2 activity-Low CRP group rate of 1.15 events per 100 person-years, p50.01). This was not seen in those with the 2/2 genotype (Figure 1) , where rates were similar across groups (p50.73). While no analyses were possible by subtype of CAD events due to small sample size, in both Hp 2/1 and 2/2, angina comprised approximately 50% of the CAD events in the high Lp-PLA 2 activity and high CRP category.
Discussion
In this cohort of childhood-onset type 1 diabetic persons with proteinuria, elevated CRP levels are associated with an increased risk of CAD, while Lp-PLA 2 activity is only associated with an increased risk of CAD if CRP is also high. Intriguingly, however, Lp-PLA 2 activity further increases risk in the haptoglobin 2/1 subgroup (but not Hp 2/2), even after adjustment for CRP and other factors. These results suggest that Lp-PLA 2 activity may add to the prediction of CAD in type 1 diabetic persons who are thought to have a lower genetic predisposition to cardiovascular disease. We are unaware of any previous reports of this relationship in T1D.
The mean level of Lp-PLA 2 activity in the current report, of 145.4 nmol/min/mL (SD 32.9), is higher than the levels reported by most other studies. In reports by Furberg et al., 57 Kim et al., 17 and Oei et al., 13 mean Lp-PLA2 activity was <50 nmol/min/ml. In contrast, however, reports by Allison et al. 58 and Koenig et al. 16 reported levels similar to those seen in the current study (mean Lp-PLA2 activity 145.2 (33.5) and 122.4 (26.2) nmol/min/ml, respectively). One possible reason for these higher levels is that the participants in these studies had either prior coronary heart disease 16 or had previously been referred to a vascular testing center, 58 whereas most of the participants in the studies with lower levels of Lp-PLA2 activity were healthy at the time the sample was collected, except for the report by Furberg et al., where approximately 10% had a history of myocardial infarction. 57 The participants in our study are thus more comparable to those of the Allison et al. 58 and Koenig et al. 16 reports, as having both T1D and proteinuria puts them at an increased risk of developing CAD. Lp-PLA 2 activity was correlated with traditional cardiovascular disease risk factors, including total, LDL and HDL cholesterol, both of which, to different extents, carry Lp-PLA 2 in the blood. Lp-PLA 2 activity was also correlated with diastolic blood pressure, WBC and WHR. It was not correlated with CRP or measures of proteinuria and kidney function. The lack of correlation with CRP is similar to the findings of the West of Scotland Coronary Prevention Study (WOSCOPS), 10 ARIC, 12 the Rotterdam study, 13 the report by Brilakis et al. 14 15 but is in contrast to Koenig et al. who reported a positive correlation between the two markers. 16 A few studies of the general population have examined the Lp-PLA 2 -CRP relationship with respect to cardiovascular disease incidence. [11] [12] [13] 59 Most of these studies looked at Lp-PLA 2 mass. In ARIC, a significant three-way interaction between Lp-PLA 2 mass, CRP and LDL was found, so that in those with LDL<130 mg/dl, high Lp-PLA 2 was associated with coronary heart disease when CRP is also elevated. 12 In the current analysis, no interaction between Lp-PLA 2 activity and LDL cholesterol was observed (data not shown). Similarly, analysis of middle-age men in the Monitoring of Trends and Determinants in Cardiovascular Disease Augsburg (MONICA) survey database also showed that persons with elevations in both Lp-PLA 2 mass and CRP were at an increased risk of coronary heart disease compared with those with an elevation in either marker alone, but did not report directly testing for an interaction. 11 In contrast, the Women's Health Study (WHS) did not find an association between Lp-PLA 2 mass and cardiovascular disease, although CRP was significantly associated with disease incidence. 59 As in our study, the Rotterdam Study examined Lp-PLA 2 activity and reported an independent association between Lp-PLA 2 activity and coronary heart disease, however there was no interaction between Lp-PLA 2 activity and CRP. 13 We have also shown that while the level of Lp-PLA 2 did not differ between haptoglobin genotype, Lp-PLA 2 activity was associated with CAD in the 2/1 genotype but not in the 2/2 genotype. Similarly, the incidence of CAD is elevated in those with high Lp-PLA 2 and high CRP in persons with the 2/1 genotype but not the 2/2 genotype. We are unaware of any prior reports suggesting this relationship between haptoglobin and Lp-PLA 2 with respect to CAD.
It is interesting to speculate why Lp-PLA 2 would only predict CAD in the lower risk Hp 2/1 subgroup. It is clearly not simply due to absolute levels being increased only in Hp 2/1 CAD cases, as the mean values for CAD cases are similar in both Hp 2/1 and 2/2 (data not shown). The most likely explanation, beyond chance, is that of a complex interplay with other risk factors and time to CAD event. For example, given one's genetic background (Hp 2/2), one may be predisposed to CAD events, thus the additive effect of Lp-PLA 2 activity is difficult to demonstrate. However, in a lower risk group (Hp 2/1), this added risk (Lp-PLA 2 activity) becomes evident. While in Hp 2/1, those with Lp-PLA 2 activity below the median level seemed to be protected in terms of time to first CAD event (mean follow-up time to event approximately 11.5 years), those with Lp-PLA 2 activity above the median level had a mean time to event that was similar to that seem in Hp 2/2 (mean follow-up time to event approximately 7 years). This difference in time to CAD event demonstrates that Lp-PLA 2 activity yields a comparable risk in Hp 2/1 to that of Hp 2/2 overall. This result is also consistent with events being generally more inflammatory induced in Hp 2/1 and less so in Hp 2/2 where oxidative mechanisms may predominate. However, these results should be viewed with caution, owing to the small sample size (i.e. a total of 70 individuals and 35 CAD events), although the sample size is quite large for long term follow-up of the type of participant being studied, i.e. persons with T1D and renal disease. Our study has many strengths, including a prospective design with long-term follow-up (through 18 years) to examine the incidence of CAD events which were confirmed by medical records. The major limitation of the study is the small sample size, particularly the small number of study participants with the 1/1 haptoglobin genotype, which does not allow us to run multivariate analysis within that subgroup. In addition, there is a potential for a survivor bias in the high CAD risk 2/2 genotype group, such that the most at-risk individuals are not represented due to death prior to commencement of the study.
In conclusion, this study among individuals with T1D and renal disease has demonstrated an interaction between Lp-PLA 2 activity and CRP with respect to CAD risk. However, this relationship does not seem to exist in individuals with the higher-risk 2/2 haptoglobin genotype. In addition, in persons with the 2/1 haptoglobin genotype, Lp-PLA 2 activity is an independent predictor of CAD incidence, suggesting that it may be useful as a marker of risk in persons expected to have a lower genetic susceptibility to developing CAD.
